New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives

Join us for this expert-led educational program featuring live interactive Webinars about the current guidelines and new treatment advances for your patients with relapsed/refractory multiple myeloma and then download the slides and listen to the podcast of frequently asked questions!

Share

Program Content

Activities

FAQ: R/R Myeloma
New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: September 01, 2020

Expires: August 31, 2021

Activities

Salvage Treatment for RR MM
Overview of Relapsed/Refractory Myeloma and Therapeutic Strategies for Patients With Heavily Pretreated Disease After Relapse
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2020

Expires: June 24, 2021

Novel Agents for RR MM
Promising New Treatment Options for Patients With Relapsed/Refractory Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2020

Expires: June 24, 2021

Activities

Advances in Relapsed/Refractory Multiple Myeloma
New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline LLC

Sanofi Genzyme Corp